Generic, Branded Generic & Proprietary Medicinal Products – Group 11
A Contract Award Notice
by BUSINESS SERVICES ORGANISATION, PROCUREMENT AND LOGISTICS SERVICE
- Source
- OJEU
- Type
- Contract (Supply)
- Duration
- 5 year (est.)
- Value
- £24M
- Sector
- HEALTH
- Published
- 18 Apr 2023
- Delivery
- To 14 Dec 2030 (est.)
- Deadline
- n/a
Concepts
Location
Belfast
2 buyers
35 suppliers
- Abbvie Berks
- Aguettant Bristol
- Astrazeneca London
- Aventis Pharma Berkshire
- Bayer Berkshire
- Chiesi Manchester
- CNX Therapeutics London
- Colonis Pharma London
- DR Falk Pharma Bucks
- Drreddys Laboratories Cambridge
- Focus Pharmaceuticals London
- Fresenius Kabi Cheshire
- Galen Craigavon
- Glaxosmithkline Brentford
- Glenmark Pharmaceuticals Europe Harrow
- Grünenthal Stokenchurch
- Hameln Pharma Gloucester
- Janssen Cilag Buckinghamshire
- Kent Pharma Kent
- Macure Pharma London
- Martindale Pharma Essex
- Mercury Pharmaceuticals London
- Morningside Pharmaceuticals Loughborough
- Napp Pharmaceuticals Cambridge
- Neon Healthcare Hertfordshire
- Neuraxpharm Cardiff
- Novartis London
- Pfizer Kent
- Roche Products Garden City
- Sandoz Surrey
- Teva Castleford
- Tillomed Laboratories Luton
- Tillotts Pharma Lincolnshire
- Viatris Global Heathcare Potters Bar
- Ferring Pharmaceuticals West Drayton
Description
Generic, Branded Generic & Proprietary Medicinal Products – Group 11
Total Quantity or Scope
Generic, Branded Generic & Proprietary Medicinal Products – Group 11 [4229695] is established under the Medicinal Products Dynamic Purchasing System [131864]. The contract is awarded on behalf of the following contract participants: (i) Belfast Health and Social Care Trust (BHSCT); (ii) South Eastern Health and Social Care Trust (SEHSCT); (iii) Northern Health and Social Care Trust (NHSCT); (iv) Southern Health and Social Care Trust (SHSCT); (v) Western Health and Social Care Trust (WHSCT); (vi) Northern Ireland Ambulance Service (NIAS); (vii) Northern Ireland Blood Transfusion Service (NIBTS); (viii) Business Services Organisation (BSO); (ix) Public Health Agency (PHA); (x) Department of Health, Northern Ireland (DoH(NI)); (xi) Health and Social Care Board (HSCB) (now Strategic Planning and Performance Group).
Award Detail
1 | Abbvie (Berks)
|
2 | Aguettant (Bristol)
|
3 | Astrazeneca (London)
|
4 | Aventis Pharma (Berkshire)
|
5 | Bayer (Berkshire)
|
6 | Chiesi (Manchester)
|
7 | CNX Therapeutics (London)
|
8 | Colonis Pharma (London)
|
9 | DR Falk Pharma (Bucks)
|
10 | Drreddys Laboratories (Cambridge)
|
11 | Focus Pharmaceuticals (London)
|
12 | Fresenius Kabi (Cheshire)
|
13 | Galen (Craigavon)
|
14 | Glaxosmithkline (Brentford)
|
15 | Glenmark Pharmaceuticals Europe (Harrow)
|
16 | Grünenthal (Stokenchurch)
|
17 | Hameln Pharma (Gloucester)
|
18 | Janssen Cilag (Buckinghamshire)
|
19 | Kent Pharma (Kent)
|
20 | Macure Pharma (London)
|
21 | Martindale Pharma (Essex)
|
22 | Mercury Pharmaceuticals (London)
|
23 | Morningside Pharmaceuticals (Loughborough)
|
24 | Napp Pharmaceuticals (Cambridge)
|
25 | Neon Healthcare (Hertfordshire)
|
26 | Neuraxpharm (Cardiff)
|
27 | Novartis (London)
|
28 | Pfizer (Kent)
|
29 | Roche Products (Garden City)
|
30 | Sandoz (Surrey)
|
31 | Teva (Castleford)
|
32 | Tillomed Laboratories (Luton)
|
33 | Tillotts Pharma (Lincolnshire)
|
34 | Viatris Global Heathcare (Potters Bar)
|
35 | Ferring Pharmaceuticals (West Drayton)
|
Award Criteria
Compliance with Contract Scope and Specification | _ |
Supply and Delivery of Product: Same Working Day Delivery | 5.0 |
Supply and Delivery of Product: Wholesale Distribution | 5.0 |
Continuity of Supply: Minimum Committed Stockholding | 8.0 |
Governance, Quality Control and Risk: Pharmaceutical Quality Assessment (PQA): Section 1 | _ |
Governance, Quality Control and Risk; Pharmaceutical Quality Assessment (PQA): Section 2 – Section 6 (inclusive) | 40.0 |
PRICE | 42.0 |
CPV Codes
- 33600000 - Pharmaceutical products
Indicators
- Award on basis of price and quality.
Other Information
The estimated total value of contract (excluding VAT) is GBP 24 000 000 to GBP 120 000 000. This maximum value in the range takes into consideration and accounts for all available extension provision as outlined in the SS17bc Commercial Conditions of Contract for Supplies Contracts document and provides for potential growth of up to 50% over the course of the contract. The total value of contract (detailed in section V.2.4) awarded to each of the Contractors indicated in this notice is based on an initial contract period of 24 months. It is important to note that there is available provision to extend this initial contract period in accordance with Section 2 of the SS17bc Commercial Conditions of Contract for Supplies Contracts document.
Reference
- OJEU 230019-2023